Ann: PTX-100 trial advances following successful Phase 1b, page-281

Morning mate,

Going by the quarterly PTX-200 is progressing well. The trial has progress to a higher dose level of 45 mg/m2 as reported in April. Given that PTX reported on the dosing levels at 35 mg/m2 back in April I'm going to assume the increased dosing had probably commenced by late April or early May.

The recent quarterly says further updates in relations to ptx-200 in the coming months so I'm assuming the next update will be a lot sooner than December.



"During the quarter Prescient’s targeted therapy studies for PTX-100 and PTX-200 continue to make excellent progress and enrol patients with no safety issues reported by investigators. On 23 April 2021 Prescient reported on the Phase 1b clinical study of PTX-200 and cytarabine in patients with acute myeloid leukemia (AML) has successfully completed the second cohort at 35 mg/m2 under a modified study protocol, with no safety or toxicity issues observed. The study is now progressing through the higher dose level of 45 mg/m2 and Prescient looks forward to providing updates in coming months."

Cheers.